Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways): A Randomized, Placebo-Controlled, Double-Blind Clinical Trial

NCT06221696 is registered in ClinicalTrials.gov with S.LAB (SOLOWAYS) as lead sponsor.

NCT NCT06221696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06221696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways): A Randomized, Placebo-Controlled, Double-Blind Clinical Trial
Lead sponsor
S.LAB (SOLOWAYS)
Phase
Not applicable
Overall status
Completed
Start date
June 12, 2023
Completion date
December 1, 2023
Enrollment
160 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overweight and obesity